Conditional approval in EU for Fampyra

Dalfampridine, or Ampyra, is a potassium channel blocker that is shown to improve visual function, motor skills and relieve fatigue in MS patients.

Conditional approval in EU for Fampyra

Postby MSUK » Mon Jul 25, 2011 7:51 am

Image

Biogen Idec Inc. said it received conditional approval from the European Commission for Fampyra to improve walking in adult patients with multiple sclerosis or MS who have walking disability. Fampyra is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS.

Fampyra can be used alone or in combination with disease modifying therapies, including immunomodulatory drugs.

"With its approval by the European Commission, Fampyra has the potential to make a real difference for thousands of people across Europe with both relapsing remitting and progressive forms of MS," explained Prof. Bernd Kieseier, Department of Neurology, University Hospital Duesseldorf.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2109
Joined: Wed Oct 14, 2009 3:00 pm

Return to Ampyra

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service